XU Rui, HE Jia-fa, ZOU Jia-chen. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+/HER2-, Node-Positive, High-Risk, Early Breast Cancer: Review of monarchE Study[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 74-77. DOI: 10.12019/j.issn.1671-5144.2023.02.002
|
Citation:
|
XU Rui, HE Jia-fa, ZOU Jia-chen. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+/HER2-, Node-Positive, High-Risk, Early Breast Cancer: Review of monarchE Study[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 74-77. DOI: 10.12019/j.issn.1671-5144.2023.02.002
|
XU Rui, HE Jia-fa, ZOU Jia-chen. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+/HER2-, Node-Positive, High-Risk, Early Breast Cancer: Review of monarchE Study[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 74-77. DOI: 10.12019/j.issn.1671-5144.2023.02.002
|
Citation:
|
XU Rui, HE Jia-fa, ZOU Jia-chen. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+/HER2-, Node-Positive, High-Risk, Early Breast Cancer: Review of monarchE Study[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 74-77. DOI: 10.12019/j.issn.1671-5144.2023.02.002
|
DownLoad: